Rayzebio, Inc. provides radiopharmaceutical medicines for cancer. It develops a pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225. The company was founded by Deborah Charych, Aaron Kantoff and Aron Royston in January 2020 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of RayzeBio Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. RayzeBio Inc. market cap is $3.74B.
What is the 52-week high for RayzeBio Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. RayzeBio Inc. 52 week high is $62.51 as of September 26, 2025.
What is the 52-week low for RayzeBio Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. RayzeBio Inc. 52 week low is $17.95 as of September 26, 2025.
What is RayzeBio Inc. stock price today?
RayzeBio Inc. stock price today is $62.49.
What was RayzeBio Inc. stock price yesterday?
RayzeBio Inc. stock price yesterday was $62.48.
What is the Price-to-Book ratio of RayzeBio Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. RayzeBio Inc. P/B ratio is 6.4982.
What is the 50-day moving average of RayzeBio Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. RayzeBio Inc. 50-day moving average is $61.51.
